Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

Inclusion Criteria

• •1. Women ages of 18 to 70 years old
• •2. Women who are able and willing to read understand and sign an informed consent document
• •3. Biopsy-accessible breast tumor of significant size for core needle biopsy/ultrasound measurable (≥ 2cm)
• •4. Patients with histologically confirmed carcinoma of the female breast with triple-negative status by immunohistochemistry (IHC). Patients who are low estrogen reception (ER) expression (\< 20%), progesterone receptor (PR) negative and human epidermal growth factor 2 (HER2) negative are eligible.
• •5. Clinical stages IIA -IIIC (AJCC 2009)
• •6. Chemotherapy-naïve patients (for this cancer)
• •7. Performance status: Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• •8. Non-pregnant and not nursing.
• •* Granulocyte greater than or equal to 1,500/microliter
• •* Platelet count greater than or equal to 100,000/microliter
• •* Absolute neutrophil count (ANC) greater than or equal to l500/microliter
• •* Hemoglobin greater than or equal to 10g/deciliter
• •* Bilirubin less than or equal 1.5 x upper limit of normal
• •* aspartate aminotransferase (ALT or SGOT) and alanine transaminase (AST or SGPT) less than 2.5 x upper limit of normal
• •7\. Creatinine within institutional normal limits or glomerular filtration rate greater than or equal to 30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation 10. Baseline left ventricular ejection fraction of greater than or equal to 55%